• <li id="2m8eg"></li>
  • <tt id="2m8eg"><blockquote id="2m8eg"></blockquote></tt>
  • 掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
    客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質量反饋  人才招聘  關于我們  聯系我們
    首頁 > 產品中心 > 一抗 > 產品信息
    Rabbit Anti-VEGFR2 antibody (bs-10412R)
    訂購QQ:  400-901-9800
    說明書: 50ul  100ul  200ul

    產品編號 bs-10412R
    英文名稱 VEGFR2
    中文名稱 血管內皮生長因子受體2抗體
    別    名 VEGF Receptor 2; CD309; CD309 antigen; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein tyrosine kinase receptor FLK1; Protein-tyrosine kinase receptor flk-1; Tyrosine kinase growth factor receptor; Vascular endothelial growth factor receptor 2; VEGFR 2; VEGFR; VEGFR-2; VEGFR2; VGFR2_HUMAN.  
    Specific References  (12)     |     bs-10412R has been referenced in 12 publications.
    [IF=4.025] Tu Yi-An. et al. Intentional endometrial injury enhances angiogenesis through increased production and activation of MMP-9 by TNF-α and MMP-3 in a mouse model. Mol Hum Reprod. 2021 Aug;:  IHC ;  Mouse.  
    [IF=15.881] Kuo Zhang. et al. A Monotargeting Peptidic Network Antibody Inhibits More Receptors for Anti-Angiogenesis. Acs Nano. 2021;XXXX(XXX):XXX-XXX  IF ;  Rabbit.  
    [IF=4.784] Ding J et al. Anti-angiogenic effect of a chemically sulfated polysaccharide from Phellinus ribis by inhibiting VEGF/VEGFR pathway. Int J Biol Macromol. 2020 Mar 11;154:72-81.  IHC,WB ;  mouse.  
    [IF=1.851] Luo Z et al. Silencing of RBP?JK promotes the differentiation of bone marrow mesenchymal stem cells into vascular endothelial cells. Mol Med Rep. 2019 Nov 6.  ICF ;  Rat.  
    [IF=2.766] Bhagwani AR et al. Endothelial cells are a source of Nestin expression in Pulmonary Arterial Hypertension.PLoS One.?2019 Mar 18;14(3):e0213890.  FCM ;  Rat.  
    [IF=5.168] Xiao et al. Adipose-derived stem cells-seeded bladder acellular matrix graft-silk fibroin enhances bladder reconstruction in a rat model. (2017) Oncotarget. 8:86471-86487  WB ;  Rat.  
    [IF=1.84] Fernández, RA García, et al. "Iberian pig early pregnancy: Vascular endothelial growth factor receptor system expression in the maternofetal interface in healthy and arresting conceptuses." Theriogenology 83.3 (2015): 334-343.  WB ;  Pig.  
    [IF=3.33] Kuang, Chun-yan, et al. "Schlafen 1 Inhibits the Proliferation and Tube Formation of Endothelial Progenitor Cells." PLOS ONE 9.10 (2014): e109711.  Rat.  
    [IF=6.583] Ahmad S et al. C3a Receptor Antagonist Therapy is Protective with or without Thrombolysis in Murine Thromboembolic Stroke. Br J Pharmacol. 2020 Jan 24.  FCM ;  Mouse.  
    [IF=4.963] Zhang W et al. Deer thymosin beta 10 functions as a novel factor for angiogenesis and chondrogenesis during antler growth and regenerationStem Cell Res Ther. 2018 Jun 19;9(1):166.  WB ;  deer&Human.  
    [IF=2.54] Wang, Li, et al. "Ghrelin inhibits atherosclerotic plaque angiogenesis and promotes plaque stability in a rabbit atherosclerotic model." Peptides (2017).  WB ;  Rabbit.  
    [IF=1.22] Tan, Jie, et al. "Single-Dose Local Simvastatin Injection Improves Implant Fixation via Increased Angiogenesis and Bone Formation in an Ovariectomized Rat Model." Medical Science Monitor 21 (2015): 1428-1439.  IHC-P ;  Rat.  
    研究領域 腫瘤  細胞生物  免疫學  神經生物學  信號轉導  生長因子和激素  激酶和磷酸酶  細胞膜受體  細胞類型標志物  內皮細胞  
    抗體來源 Rabbit
    克隆類型 Polyclonal
    交叉反應 Human,  (predicted: Mouse, Rat, Dog, Pig, Cow, Horse, Sheep, )
    產品應用 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/Test (石蠟切片需做抗原修復)
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    理論分子量 147kDa
    細胞定位 細胞核 細胞漿 細胞膜 分泌型蛋白 
    性    狀 Liquid
    濃    度 1mg/ml
    免 疫 原 KLH conjugated synthetic peptide derived from human VEGFR2: 101-200/1356 <Extracellular>
    亞    型 IgG
    純化方法 affinity purified by Protein A
    緩 沖 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存條件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
    注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
    PubMed PubMed
    產品介紹 Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009].

    Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA-and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

    Interacts with MYOF. Interacts with VEGFA, VEGFC and VEGFD. Monomer in the absence of bound VEGFA, VEGFC or VEGFD. Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD. Can also form heterodimers with FLT1 and FLT4. Interacts (tyrosine phosphorylated) with FYN, NCK1, PLCG1 and SHB. Interacts with HIV-1 Tat. Interacts with CBL. Interacts with SH2D2A/TSAD and GRB2.

    Subcellular Location:
    Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.
    Isoform 2: Secreted (Probable).
    Isoform 3: Secreted.

    Tissue Specificity:
    Detected in cornea (at protein level). Widely expressed.

    Post-translational modifications:
    Ubiquitinated. Tyrosine phosphorylation of the receptor promotes its poly-ubiquitination, leading to its degradation via the proteasome or lysosomal proteases.
    Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-951 is important for interaction with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for interaction with NCK1 and FYN. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.

    Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
    Note=Plays a major role in tumor angiogenesis. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.


    Gene ID:

    Database links:

    Entrez Gene: 3791 Human

    Entrez Gene: 407170 Cow

    Entrez Gene: 482154 Dog

    Entrez Gene: 16542 Mouse

    Entrez Gene: 25589 Rat

    Omim: 191306 Human

    SwissProt: P35968 Human

    SwissProt: P35918 Mouse

    Tissue/cell: mouse placenta tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
    Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
    Incubation: Anti-VEGFR2 Polyclonal Antibody, Unconjugated(bs-10412R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
    Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
    Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
    Incubation: Anti-VEGFR2 Polyclonal Antibody, Unconjugated(bs-10412R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
    Blank control: MCF7.
    Primary Antibody (green line): Rabbit Anti-VEGFR2 antibody (bs-10412R)
    Dilution: 2μg /10^6 cells;
    Isotype Control Antibody (orange line): Rabbit IgG .
    Secondary Antibody : Goat anti-rabbit IgG-AF647
    Dilution: 1μg /test.
    The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at-20℃.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
    Cell: Hela
    Flow cytometric analysis of Rabbit IgG isotype control (Cat#: bs-10412R) on Hela(green) compared with control in the absence of primary antibody (blue) followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG(H+L) secondary antibody .
    版權所有 2019-2022 www.gesunde-tips.com 北京博奧森生物技術有限公司
    通過國際質量管理體系ISO9001:2008 GB/T19001-2008認證    編號:00115Q211807R1M/1100
    京ICP備05066980號-1         京公網安備110107000727號